69
Participants
Start Date
June 16, 2019
Primary Completion Date
June 16, 2020
Study Completion Date
August 15, 2020
Control group
23 eyes that didn't receive any intraoperative steroids
Dexamethasone group
23 eyes each received intracameral dexamethasone at the conclusion of phacoemulsification Received intracameral 0.4 mg in / 0.1 ml dexamethasone (8mg/2ml®; Amriya or Epico) at the end of phacoemulsification.
Triamcinolone (TA) group
23 eyes each received intracameral triamcinolone (TA) at the conclusion of phacoemulsification Received intracameral 2 mg/0.05 ml triamcinolone (TA) (Kenacort-A®; Bristol-Myers Squibb) at the end of phacoemulsification.
Khaled G Abueleinen, Giza
Beni-Suef University
OTHER
Cairo University
OTHER